CA2707559C - Fviii peptides and their use in tolerising haemophiliacs - Google Patents

Fviii peptides and their use in tolerising haemophiliacs Download PDF

Info

Publication number
CA2707559C
CA2707559C CA2707559A CA2707559A CA2707559C CA 2707559 C CA2707559 C CA 2707559C CA 2707559 A CA2707559 A CA 2707559A CA 2707559 A CA2707559 A CA 2707559A CA 2707559 C CA2707559 C CA 2707559C
Authority
CA
Canada
Prior art keywords
peptide
peptides
fviii
factor viii
haemophilia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2707559A
Other languages
English (en)
French (fr)
Other versions
CA2707559A1 (en
Inventor
David Wraith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Worg Pharmaceuticals (Zhejiang) Co Ltd
Original Assignee
Apitope International NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apitope International NV filed Critical Apitope International NV
Priority to CA3005013A priority Critical patent/CA3005013C/en
Publication of CA2707559A1 publication Critical patent/CA2707559A1/en
Application granted granted Critical
Publication of CA2707559C publication Critical patent/CA2707559C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2707559A 2007-12-04 2008-12-03 Fviii peptides and their use in tolerising haemophiliacs Active CA2707559C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3005013A CA3005013C (en) 2007-12-04 2008-12-03 Fviii peptides and their use in tolerising haemophiliacs

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0723712.6 2007-12-04
GBGB0723712.6A GB0723712D0 (en) 2007-12-04 2007-12-04 Peptides
PCT/GB2008/003996 WO2009071886A1 (en) 2007-12-04 2008-12-03 Fviii peptides and their use in tolerising haemophiliacs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3005013A Division CA3005013C (en) 2007-12-04 2008-12-03 Fviii peptides and their use in tolerising haemophiliacs

Publications (2)

Publication Number Publication Date
CA2707559A1 CA2707559A1 (en) 2009-06-11
CA2707559C true CA2707559C (en) 2018-07-03

Family

ID=38982965

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2707559A Active CA2707559C (en) 2007-12-04 2008-12-03 Fviii peptides and their use in tolerising haemophiliacs
CA3005013A Active CA3005013C (en) 2007-12-04 2008-12-03 Fviii peptides and their use in tolerising haemophiliacs

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3005013A Active CA3005013C (en) 2007-12-04 2008-12-03 Fviii peptides and their use in tolerising haemophiliacs

Country Status (25)

Country Link
US (1) US8445448B2 (enExample)
EP (1) EP2227488B3 (enExample)
JP (2) JP5501245B2 (enExample)
KR (1) KR101519840B1 (enExample)
CN (2) CN103709234B (enExample)
AU (1) AU2008332968B2 (enExample)
BR (1) BRPI0820143A2 (enExample)
CA (2) CA2707559C (enExample)
CY (1) CY1115168T1 (enExample)
DK (1) DK2227488T6 (enExample)
EA (1) EA019370B1 (enExample)
EC (1) ECSP10010327A (enExample)
ES (1) ES2458315T7 (enExample)
GB (1) GB0723712D0 (enExample)
HR (1) HRP20140344T4 (enExample)
IL (1) IL205780A (enExample)
MX (1) MX2010006084A (enExample)
MY (1) MY150995A (enExample)
NZ (1) NZ585217A (enExample)
PL (1) PL2227488T6 (enExample)
PT (1) PT2227488E (enExample)
SI (1) SI2227488T1 (enExample)
UA (1) UA101003C2 (enExample)
WO (1) WO2009071886A1 (enExample)
ZA (1) ZA201002997B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030062321A (ko) 2000-08-21 2003-07-23 아피토프 테크놀러지 (브리스톨) 리미티드 펩티드 선별 방법
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII
US8329871B2 (en) * 2008-06-24 2012-12-11 Octapharma Ag Process of purifying coagulation factor VIII
GB0908515D0 (en) * 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
US20120135917A1 (en) * 2009-06-16 2012-05-31 Eisaku Yoshihara Anti-Gram Negative Bacteria Agent
PL3260132T3 (pl) * 2010-10-27 2022-08-08 Takeda Pharmaceutical Company Limited Peptydy fviii do wywoływania tolerancji immunologicznej oraz immunodiagnostyki
EA038705B1 (ru) 2012-01-12 2021-10-07 Биовератив Терапьютикс Инк. Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
CN104903347B (zh) * 2012-11-12 2020-02-21 艾匹托普国际股份有限公司 肽
GB201314052D0 (en) 2013-08-06 2013-09-18 Apitope Int Nv Peptides
MX2018006789A (es) 2015-12-03 2019-02-13 Juno Therapeutics Inc Receptores quimericos modificados y composiciones y metodos relacionados.
CA3044838A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
US12077607B2 (en) * 2021-09-23 2024-09-03 University Of Utah Research Foundation Functional and therapeutic effects of PAR4 cleavage by cathepsin G

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015615A1 (en) * 1989-06-20 1990-12-27 Scripps Clinic And Research Foundation The phospholipid binding domain of factor viii
US6132729A (en) * 1997-01-22 2000-10-17 Board Of Regents, The University Of Texas System Combined tissue factor and chemotherapeutic methods and compositions for coagulation and tumor treatment
KR20030062321A (ko) 2000-08-21 2003-07-23 아피토프 테크놀러지 (브리스톨) 리미티드 펩티드 선별 방법
US20040096456A1 (en) * 2000-12-01 2004-05-20 Conti-Fine Bianca M Method to treat hemophilia
PL362324A1 (en) * 2001-02-19 2004-10-18 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
AU2002312660A1 (en) * 2001-05-31 2002-12-16 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
MXPA04010061A (es) * 2002-04-18 2004-12-13 Merck Patent Gmbh Factor viii modificado.
CN102816241B (zh) * 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
WO2006003183A1 (de) 2004-07-02 2006-01-12 Alois Jungbauer Peptide zur blockierung von fviii-inhibitoren
IL229645A0 (en) * 2013-11-26 2014-03-31 Omrix Biopharmaceuticals Ltd A dry bandage containing thrombin and pectin

Also Published As

Publication number Publication date
BRPI0820143A2 (pt) 2015-05-12
ZA201002997B (en) 2011-07-27
CN101889024B (zh) 2014-04-23
JP6063402B2 (ja) 2017-01-18
JP2014088440A (ja) 2014-05-15
NZ585217A (en) 2012-11-30
CA3005013C (en) 2021-11-16
GB0723712D0 (en) 2008-01-16
UA101003C2 (uk) 2013-02-25
PL2227488T3 (pl) 2014-07-31
ES2458315T3 (es) 2014-04-30
ECSP10010327A (es) 2010-09-30
SI2227488T1 (sl) 2014-06-30
CN103709234B (zh) 2017-01-18
AU2008332968B2 (en) 2014-03-20
EA201070681A1 (ru) 2010-10-29
IL205780A0 (en) 2010-11-30
EP2227488B1 (en) 2014-01-22
CA3005013A1 (en) 2009-06-11
PL2227488T6 (pl) 2015-04-30
MX2010006084A (es) 2010-06-23
MY150995A (en) 2014-03-31
HRP20140344T1 (en) 2014-05-09
KR20100087346A (ko) 2010-08-04
JP5501245B2 (ja) 2014-05-21
CY1115168T1 (el) 2016-12-14
CN101889024A (zh) 2010-11-17
HK1144292A1 (en) 2011-02-11
ES2458315T7 (es) 2015-02-18
JP2011505414A (ja) 2011-02-24
KR101519840B1 (ko) 2015-05-18
EP2227488A1 (en) 2010-09-15
PT2227488E (pt) 2014-04-21
AU2008332968A1 (en) 2009-06-11
CN103709234A (zh) 2014-04-09
DK2227488T6 (en) 2015-02-16
HRP20140344T4 (hr) 2015-07-31
WO2009071886A1 (en) 2009-06-11
US8445448B2 (en) 2013-05-21
EA019370B1 (ru) 2014-03-31
EP2227488B3 (en) 2014-11-19
IL205780A (en) 2015-06-30
US20100323966A1 (en) 2010-12-23
CA2707559A1 (en) 2009-06-11
DK2227488T3 (da) 2014-04-22

Similar Documents

Publication Publication Date Title
CA3005013C (en) Fviii peptides and their use in tolerising haemophiliacs
US8703705B2 (en) Modified factor VIII peptides
AU2014200237B2 (en) FVIII peptides and their use in tolerising haemophiliacs
HK1172240B (en) Fviii-derived peptides and their use in tolerising haemophiliacs
HK1172240A (en) Fviii-derived peptides and their use in tolerising haemophiliacs
HK1144292B (en) Fviii peptides and their use in tolerising haemophiliacs
HK1173358B (en) Fviii-derived peptides

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130911

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260114

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260318

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260715

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260715